menu
    • menu
    [{"orgOrder":0,"company":"Oncomatryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ Inapplicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"CDTI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ CDTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ CDTI"},{"orgOrder":0,"company":"Tubepharma","sponsor":"Oncomatryx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Tubepharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tubepharma \/ Oncomatryx","highestDevelopmentStatusID":"6","companyTruncated":"Tubepharma \/ Oncomatryx"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncomatryx \/ Undisclosed"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"TFS International AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"OMTX705","moa":"FAP-alpha\/Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Oncomatryx","highestDevelopmentStatusID":"5","companyTruncated":"Oncomatryx \/ Oncomatryx"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncomatryx

    Menu

    Oncomatryx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : TFS International AB

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TFS Expands Partnership with Oncomatryx for OMTX705 Pancreatic Cancer Trial

                            Details : The collaboration aims to advance the clinical development of OMTX705 in patients with advanced or metastatic pancreatic adenocarcinoma.

                            Product Name : OMTX705

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : TFS International AB

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMTX705,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CDTI

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Oncomatryx Raises €25 Million to Foster OMTX705 Clinical Trials

                            Details : The proceeds will be used to fund Phase Ib-II clinical trials of OMTX705, a first-in-class, novel ADC targeting fibroblast activation protein (FAP), to treat metastatic solid tumors.

                            Product Name : OMTX705

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 27, 2025

                            Lead Product(s) : OMTX705,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CDTI

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tubepharma

                            Austria arrow
                            EASL Congress
                            Not Confirmed

                            Tubepharma

                            Austria arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMTX705,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oncomatryx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Oncomatryx Acquires Tube Pharmaceuticals GmbH to Consolidate its Pioneering Pipeline of ADCs Targeting the Tum...

                            Details : Through the acquisition, Oncomatryx will foster its leadership in ADCs targeting the tumor microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class ADC targeting cancer-...

                            Product Name : OMTX705

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : OMTX705,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oncomatryx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted...

                            Details : OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.

                            Product Name : OMTX705

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed

                            Oncomatryx

                            Spain arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $16.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-envir...

                            Details : These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including O...

                            Product Name : OMTX705

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 22, 2022

                            Lead Product(s) : OMTX705

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $16.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth